{"id":"W4391337917","doi":"10.1182/bloodadvances.2023011620","title":"Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Genentech; Swedish Orphan Biovitrum; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Cancer Center, University of Kansas; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Memorial Sloan-Kettering Cancer Center; Jazz Pharmaceuticals; Kite Pharma; Shionogi; Amgen; Ohio State University; Karyopharm Therapeutics; MorphoSys; Celgene; AstraZeneca; Astellas Pharma; TG Therapeutics","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Oncology; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001461686,0.001122441,0.001233964,0.000268628,0.0002832356,0.0007781197,0.0006128408,0.001062856,0.004877764],"category_scores_gemma":[0.0008460827,0.0004902612,0.001241674,0.0002145256,0.0003899009,0.0005923929,0.0002501877,0.002557088,0.0009392608],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008399853,"about_ca_system_score_gemma":0.001422024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008130749,"about_ca_topic_score_gemma":0.002292425,"domain_scores_codex":[0.9996752,0.0001483425,0.00001822614,0.00005550843,0.00003670962,0.00006602509],"domain_scores_gemma":[0.9994633,0.00007442808,0.0001032034,0.00004036032,0.00007155849,0.0002471365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7280305,0.07901832,0.010501,0.0009200941,0.002874332,0.0004786003,0.0002502709,0.003158831,0.04949988,0.0003361989,0.01414686,0.110785],"study_design_scores_gemma":[0.6950703,0.2797792,0.01441004,0.00004716199,0.0006601211,0.0003442923,0.00004135424,0.001521879,0.004299249,0.0001993086,0.003594555,0.00003258555],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871309,0.001566198,0.0006703865,0.0009660186,0.0001469836,0.003766602,0.002420182,0.0001474126,0.003185232],"genre_scores_gemma":[0.9845421,0.001004514,0.002440094,0.001620654,0.0001576517,0.002882553,0.004035548,0.0000352787,0.003281592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004877764,"threshold_uncertainty_score":0.01631778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02207426763949964,"score_gpt":0.3331461903415754,"score_spread":0.3110719227020758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}